Is the hypoglycemic action of vanadium compounds related to the suppression of feeding?

Biological Trace Element Research

Volumn 157, Issue 3, 2014, Pages 242-248

  Huang, Meiling ^a   Wu, Yaling ^a   Wang, Na ^a   Wang, Ziwei ^a   Zhao, Pan ^a   Yang, Xiaoda ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

bis((5 Hydroxy 4 oxo 4H pyran 2 yl) methyl 2 hydroxy benzoatato) oxovanadium (IV); c Jun N terminal protein kinase; Diabetes; Feeding suppression; Peroxisome proliferator activated receptor ; Vanadium

Indexed keywords

BIS[(5 HYDROXY 4 OXO 4H PYRAN 2 YL)METHYL 2 HYDROXYBENZOATATO]OXOVANADIUM; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; BIS((5-HYDROXY-4-OXO-4H-PYRAN-2-YL)METHYL 2-HYDROXYBENZOATATO)OXOVANADIUM(IV); COORDINATION COMPOUND; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME PHOSPHORYLATION; FEEDING; FOOD INTAKE; GLUCOSE BLOOD LEVEL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; EATING; FEEDING BEHAVIOR; METABOLISM; MOUSE MUTANT; WEIGHT GAIN;

MUS;

ANIMALS; BIOLOGICAL MARKERS; COORDINATION COMPLEXES; DIABETES MELLITUS; EATING; FEEDING BEHAVIOR; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; SIGNAL TRANSDUCTION; VANADIUM COMPOUNDS; WEIGHT GAIN;

EID: 84896711327     PISSN: 01634984     EISSN: 15590720     Source Type: Journal    
DOI: 10.1007/s12011-013-9882-6     Document Type: Article

References (33)

1. Heyliger CE, Tahiliani AG, McNeill JH (1985) Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227:1474-1477
2. Meyerovitch J, Farfel Z, Sack J, Shechter Y (1987) Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and Mode of Action. J Biol Chem 262:6658-6662
3. Leahy JL, Hirsch IB, Peterson KA, Schneider D (2010) Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 95:4206-4216
4. Thompson KH, Orvig C (2006) Vanadium in diabetes: 100 years from phase 0 to phase I. J Inorg Biochem 100:1925-1935
5. Thompson KH, Lichter J, LeBel C, Scaife M, McNeill JH, Orvig C (2009) Vanadium treatment of type 2 diabetes: a view to the future. J Inorg Biochem 103:554-558
6. Barrio DA, Etcheverry SB (2010) Potential use of vanadium compounds in therapeutics. Curr Med Chem 17:3632-3642
7. Huang ML, Wu YL, Zhao P, Yang XD (2013) Update of metal-based drugs: problems and approaches for solution. Prog Chem 25:650-660
8. Malabu UH, Dryden S, McCarthy HD, Kilpatrick A, Williams G (1994) Effects of chronic vanadate administration in the STZ-induced diabetic rat. The antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding. Diabetes 43:9-15
9. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR (1995) In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem 153:217-231
10. Willsky GR, Goldfine AB, Kostyniak PJ, McNeill JH, Yang LQ, Khan HR, Crans DC (2001) Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato) oxovandium(IV). J Inorg Biochem 85:33-42
11. Marzban L, McNeill JH (2003) Insulin-like actions of vanadium: potential as a therapeutic agent. J Trace Elem Exp Med 16:253-267
12. Huyer G, Liu S, Kelly J, Moffat J, Payette P, Kennedy B, Tsaprailis G, Gresser MJ, Ramachandran C (1997) Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem 272:843-851
13. Zhao P, Yang XD (2013) Vanadium compounds modulate PPAR gamma activity primarily by increasing PPAR gamma protein levels in mouse insulinoma NIT-1 cells. Metallomics 5:836-843
14. Lehmann JM, Moore LB, Smitholiver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high-affinity ligand for peroxisome proliferator-activated peceptor gamma(Ppar-Gamma). J Biol Chem 270:12953-12956
15. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM (1996) The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668
16. Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514
17. Chen WL, Chen YL, Chiang YM, Wang SG, Lee HM (2012) Fenofibrate lowers lipid accumulation in myotubes by modulating the PPAR alpha/AMPK/FoxO1/ATGL pathway. Biochem Pharmacol 84:522-531
18. Hwang SL, Chang HW (2012) Natural vanadium-containing Jeju ground water stimulates glucose uptake through the activation of AMP-activated protein kinase in L6 myotubes. Mol Cell Biochem 360:401-409
19. Wu Y, Huang M, Zhao P, Yang X (2013) Vanadyl acetylacetonate upregulates PPARgamma and adiponectin expression in differentiated rat adipocytes. J Biol Inorg Chem 18:623-631
20. Olefsky JM (2000) Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106:467-472
21. Wei Y, Zhang C, Zhao P, Yang X, Wang K (2011) A new salicylic acid-derivatized kojic acid vanadyl complex: synthesis, characterization and anti-diabetic therapeutic potential. J Inorg Biochem 105:1081-1085
22. Wei YB, Yang XD (2012) Synthesis, characterization and anti-diabetic therapeutic potential of a new benzyl acid-derivatized kojic acid vanadyl complex. Biometals 25:1261-1268
23. Fakih S, Podinovskaia M, Kong X, Collins HL, Schaible UE, Hider RC (2008) Targeting the lysosome: fluorescent iron(III) chelators to selectively monitor endosomal/lysosomal labile iron pools. J Med Chem 51:4539-4552
24. Amin SS, Cryer K, Zhang B, Dutta SK, Eaton SS, Anderson OP, Miller SM, Reul BA, Brichard SM, Crans DC (2000) Chemistry and insulin-mimetic properties of bis(acetylacetonate)oxovanadium(IV) and derivatives. Inorg Chem 39:406-416
25. Leonardini A, Laviola L, Perrini S, Natalicchio A, Giorgino F (2009) Cross-talk between PPAR gamma and insulin signaling and modulation of insulin sensitivity. PPAR Res. doi: 10.1155/2009/818945
26. Viollet B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, Foretz M, Andreelli F (2009) Targeting the AMPK pathway for the treatment of type 2 diabetes. Front Biosci 14:3380-3400
27. Aguirre V, Uchida T, Yenush L, Davis R, White MF (2000) The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275:9047-9054
28. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF (2002) Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277:1531-1537
29. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333-336
30. Lee YH, Giraud J, Davis RJ, White MF (2003) c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 278:2896-2902
31. Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, Kajimoto Y, Matsuhisa M, Yamasaki Y, Hori M (2004) Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 279:45803-45809
32. Ijaz A, Tejada T, Catanuto P, Xia X, Elliot SJ, Lenz O, Jauregui A, Saenz MO, Molano RD, Pileggi A, Ricordi C, Fornoni A (2009) Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int 75:381-388
33. Gao ZL, Zhang CY, Yu SW, Yang XD, Wang K (2011) Vanadyl bisacetylacetonate protects beta cells from palmitate-induced cell death through the unfolded protein response pathway. J Biol Inorg Chem 16:789-798